Cerba Research was one of the first organizations in Europe to offer multispectral multiplex IHC services to pharmaceutical and biotechnology companies.
Your Project Deserves Our Expert Multiplex IHC Team
Cerba Research HISTOPROFILE® Multiplex IHC panels
Cerba Research offers both custom multiplex development and validation, as well as panels that come already validated for specific indications.
Some examples are:
- Tissue resident memory T-Cells CD8/CD49a/CD3/CD68/CD103
- Dendritic cells langerin/CD1a
- T-cell activation CD8/Ki-67/GranzymeB
- T-reg Light CD3/CD8/FoxP3
- PD-L1 CD68/panCK/PD-L1
- Checkpoint inhibitors CD3/CD8/PD-1/PD-L1/Custom
- Neuro macrophage CD68/CD163/GFAP/TMEM-119/c-maf
Solid Tumor Analytical Validation of T-Regulatory IHC Multiplex
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues.
Discover our poster presented at the AACR 2022 (American Association of Cancer Research)
Reach out to our experts and see how we can help advance your clinical trial in the field of Multiplex